Antiviral İlaç Zehirlenmeleri

Wang, F. & Kieff, E. (2018). Medical Virology. In D. L. Kasper, A. S. Fauci, S. L. Hauser, D. L. Longo, J. L. Jameson & J. Loscalzo (Eds), Harrison’s Principles of Internal Medicine (20th ed., p. 1325-1333). New York: McGraw Hill.

Acosta, E. P. & Flexner, C. (2018). Antiviral agents. In L. L. Brunton (Ed.), Goodman & Gilman’s The Pharmacology Basis of Theraputics (13th ed., pp.1105-1118). New York: McGraw Hill.

Kumar, S. (2012). General properties of viruses. In S. Kumar (Ed.), Textbook of Microbiology (1st ed., pp. 503-517). New Delhi: Jaypee Brothers Medıcal.

Hilal-Dandan, R. & Brunton, L. L. (2014). Goodman & Gilman’s Manual of Pharmacology and Therapeutics (2nd Ed.). Philadelphia: McGraw Hill.

Leikin, J. B. & Paloucek, F. P. (2008). Poisoning and Toxicology Handbook (4th ed.). New York: Informa Healthcare

Ratanajamit C, Vinther Skriver M, et al. Adverse pregnancy outcome in women exposed to acyclovir during pregnancy: a population-based observational study. Scand J Infect Dis, 2003;35(4):255-259. Doi:10.1080/00365540310000229

Hsu CC, Lai TI, Lien WC, et al. Emergent hemodialysis for acyclovir toxicity. Am J Emerg Med, 2005;23(7):899-900. Doi:10.1016/j.ajem.2005.04.012

Britt WJ, Prichard MN. New therapies for human cytomegalovirus infections. Antiviral Res. 2018;159:153-174. Doi:10.1016/j.antiviral.2018.09.003

MacDougall, C. (2018). Antiviral and antiretroviral agents. In K. R. Olson (Ed.), Poisoning and drug overdose (7th ed.). California: McGraw Hill.

Ekmekyapar M, Gürbüz Ş. Antiviral drugs and their toxicities. Eurasian Journal of Toxicology. 2019; 1(3): 77-84.

Pescovitz MD, Rabkin J, Merion RM, et al. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother, 2000;44:2811-5.

Ison MG, Hayden FG. Therapeutic options for the management of influenza. Curr Opin Pharmacol. 2001;1(5):482-490. Doi:10.1016/s1471-4892(01)00084-4

European Medicines Agency. Summary Report: Review on influenza antiviral medicinal products for potential use during pandemic. EMEA/CHMP 2005; London,1-18.

Keyser LA, Karl M, Nafziger AN, et al. Comparison of central nervous system adverse effects of amantadine and rimantadine used as sequential prophylaxis of ınfluenza a in elderly nursing home patients. Arch Intern Med. 2000;160(10):1485–1488. Doi:10.1001/archinte.160.10.1485

DeWitt C, Heard K, Dart RC. CNS and CV effects in acute amantadine overdoses in children. J Toxicol Clin Toxicol. 2004;42(5):713-816. Doi: 10.1081/CLT-200026959

Michalski LS, Hantsch CE, Hou SH. Amantadine toxicity in a renal transplant patient. J Toxicol Clin Toxicol, 2003;41(5):641-752. Doi: 10.1081=CLT-120024368

Gubareva LV, Kaiser L, Hayden FG. Influenza virus neuraminidase inhibitors. Lancet. 2000;355(9206):827-835. Doi:10.1016/S0140-6736(99)11433-8

Ohuchi M, Asaoka N, Sakai T, et al. Roles of neuraminidase in the initial stage of influenza virus infection. Microbes Infect, 2006;8(5):1287-1293. Doi:10.1016/j.micinf.2005.12.008

Kiso M, Mitamura K, Sakai-Tagawa Y, et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet, 2004;364(9436):759-765. Doi:10.1016/S0140-6736(04)16934-1

Piacenti FJ. An update and review of antiretroviral therapy. Pharmacotherapy, 2006;26(8):1111-1133. Doi:10.1592/phco.26.8.1111

Falco V, Rodriguez D, Ribera E, et al. Severe nucleoside-associated lactic acidosiss in human immunodeficiency virus-infected patients. Report of 12 cases and review of the literature Clin Infect Dis, 2002;34:838-846. Doi: 10.1086/339041

Stork, C. M. (2019). Antimicrobials, Antifungals, and Antivirals. In L. S. Nelson, N. A. Lewin, M. A. Howland, S. V. Smith, R. S. Hoffman, L. R. Goldfrank & N. E. Flomenbaum (Eds), Goldfrank’s Toxicologic Emergencies (11th ed., pp. 821-835). New York: McGraw Hill.

Kirian MA, Higginson RT, Fulco PP. Acute onset of pancreatitis with concomitant use of tenofovir and didanosine. Ann Pharmacother, 2004;38(10):1660-1663. doi:10.1345/aph.1D616

Moyle GJ, Sadler M. Peripheral neuropathy with nucleoside antiretrovirals: risk factors, incidence and management. Drug Saf, 1998;19(6):481-494. doi:10.2165/00002018-199819060-00005

Harris M, Montaner JS. Clinical uses of non-nucleoside reverse transcriptase inhibitors. Rev Med Virol, 2000;10(4):217-229. Doi:10.1002/1099-1654(200007/08)10:4<217::aid-rmv279>3.0.co;2-l

Flexner C. HIV-protease inhibitors. N Engl J Med, 1998;338(18):1281-1292. Doi:10.1056/NEJM199804303381808

Dando TM, Perry CM. Enfuvirtide. Drugs, 2003;63(24):2755-2768. Doi:10.2165/00003495-200363240-00005